Under statutory FDA drug-shortage carve-outs, compounding pharmacies synthesized and distributed generic semaglutide and tirzepatide from bulk active pharmaceutical ingredients at $50/month, arbitraging Novo Nordisk's and Eli Lilly's $1,000/month branded autoinjector monopolies.